Navigation Links
Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
Date:4/22/2008

>Sales by GAAP Discontinued 1Q 2008

Product Line 1Q 1Q Growth Product Line Underlying

(QTD) 2008 2007 Change Rate Impact Sales

Heart Valve

Therapy $146.7 $129.5 $17.2 13.3% $- $146.7

Critical

Care 106.7 90.9 15.8 17.4% (0.6) 106.1

Cardiac

Surgery

Systems 21.4 16.8 4.6 27.4% - 21.4

Vascular 22.0 20.2 1.8 8.9% (7.8) 14.2

Other

Distributed

Products - 6.7 (6.7) (100.0%) - -

Total Sales $296.8 $264.1 $32.7 12.4% $(8.4) $288.4

2007 Adjusted

Sales by Discontinued 1Q 2007

Product Line Product Line Underlying Underlying

(QTD) Impact FX Impact Sales Growth Rate *

Heart Valve

Therapy $(1.8) $6.1 $133.8 9.6%

Critical

Care - 5.2 96.1 10.4%

Cardiac

Surgery

Systems 2.3 0.8 19.9 7.5%

Vascular (6.1) 0.8 14.9 (5.0%)

Other

Distributed

Products (6.9) 0.1 (0.1) (100.0%)

Total Sales $(12.5) $13.0 $264.6 9.0%

GAAP

Sales by Region (QTD) 1Q 2008 1Q 2007 Change Growth Rate

United States $135.5 $124.1 $11.4 9.2%

Europe 91.2 73.9 17.3 23.4%

Japan 37.8 38.6 (0.8) (2.1%)

Rest of Worl
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
2. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
3. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
4. Edwards Lifesciences Announces Organizational Changes
5. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
7. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
8. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
11. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Proove ... Buzz of BIO Contest for the 2015 ... (BIO), the 2015 BIO International Convention will take place ... Pennsylvania. During the Buzz of BIO contest, industry leaders ... see present at the conference. The community voting period ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... 18 Premier Research Group plc (AIM:,PRG) announces ... Vice President,Global Human Resources. Mr. Keenen will be ... related to maximizing the,effectiveness of Premier Research,s people ... Dr. Troy McCall, COO, commented: "We are ...
... Ultra-low power DSP core from CEVA provides unmatched ... for state-of-the-art cochlear implant system, SAN JOSE, ... ; LSE: CVA), a leading licensor of innovative ... wireless, consumer and,multimedia applications, today announced that Advanced ...
... TOKYO, September 18 Sosei Group Corporation,("Sosei"; TSE ... AD 337, an enantiomer of an approved, centrally ... of principle trial,for the treatment of fibromyalgia syndrome ... placebo,controlled, parallel group exploratory study, investigated the efficacy,safety ...
Cached Biology Technology:Premier Research Appoints Global Head of Human Resources 2Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System 2Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System 3Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome 2
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... new study by researchers at the University of California, ... that promoting cleaner, more efficient technologies for producing charcoal ... significant climate change and development benefits. , The African ... and Latin America, is dependent on both wood and ...
... Linus Pauling's book Vitamin C and The Common Cold, published ... believe in the value of the vitamin for cold prevention ... reviewing all of the best clinical research on this topic, ... unjustified. , Robert M Douglas of the Australian National University, ...
... critical piece of synapse-associated protein 97 (SAP97) found in abundance ... play a role in everything from cardiac contractions to memory ... , Dale Mierke, associate professor of medical science at Brown, ... is an important step. Now that part of the protein's ...
Cached Biology News:Study of energy and health in Africa focuses spotlight on charcoal and forest management 2Study of energy and health in Africa focuses spotlight on charcoal and forest management 3Does vitamin C help prevent or treat the common cold? Maybe not, after all. 2Researchers reveal secret of key protein in brain and heart function 2
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: